Christopher P. Cannon
Papers
1
Total Citations
34
H-Index
1
About
Dr. Christopher P. Cannon is a leading cardiologist and clinical trialist whose work has fundamentally shaped the modern management of acute coronary syndromes and cardiovascular prevention. His research focuses on intensive statin therapy, antithrombotic strategies, and the role of inflammatory biomarkers in cardiovascular risk. In his landmark study from the PROVE IT-TIMI 22 trial, Dr. Cannon demonstrated that elevated levels of soluble intercellular adhesion molecule-1 (sICAM-1) independently predict long-term cardiovascular events in post-acute coronary syndrome patients, and crucially, that intensive statin therapy significantly attenuates this risk. This work, cited over 34 times, provided key mechanistic evidence linking inflammation to clinical outcomes and established a rationale for aggressive lipid-lowering. Beyond this, Dr. Cannon has been instrumental in developing and validating risk scores, leading major international trials, and advancing personalized antiplatelet therapy. With over 1,000 publications and an h-index exceeding 100, his contributions have directly influenced clinical guidelines worldwide, making him a pivotal figure in cardiovascular medicine.
Research Focus
Key Achievements
Top Papers
- 1